US to offer free COVID tests in September as part of fall campaign
Adds details on testing program in paragraph 2, background on COVID infections in paragraph 5, details from press briefing throughout
By Manas Mishra and Julie Steenhuysen
Aug 23 (Reuters) -The U.S. government will provide free COVID-19 tests by mail starting in late September, as it kicks off a fall campaign urging eligible Americans to get vaccinated against COVID, flu and RSV, health officials said on Friday.
Households can order up to four free tests through COVIDTests.gov, officials from the U.S. Centers for Disease Control and Prevention and the Department of Health and Human Services said at a press briefing.
The popular free testing program has had several rounds since it started in January 2022.
This year, the government campaign is timed to the fall and winter seasons, when temperatures drop and people stay indoors more, Dawn O'Connell, assistant secretary for preparedness and response at the HHS said.
COVID has been on the rise this summer, with hospitalizations jumping from 1.1 per 100,000 people at the beginning of May, to 4.4 at the beginning of August. The number of deaths has also risen during that period.
Health officials said even though previous vaccines and infection provide some immunity, people should get the updated shots, approved on Thursday, and also test.
"The virus continues to change faster than the flu virus," said U.S. CDC Director Mandy Cohen.
"The severity of COVID looks more similar to flu, but if you still put head-to-head... in terms of what is hospitalizing more folks and what is killing more folks, COVID is being (a) more dangerous virus than flu," Cohen said.
She also said COVID was now endemic, but there were tools to protect people.
The U.S. Food and Drug Administration approved updated mRNA COVID vaccines on Thursday that target a recently circulating variant, in order to better protect the population heading into cold weather.
The updated vaccines include those made by Pfizer PFE.N, its German partner BioNTech 22UAy.DE and Moderna MRNA.O.The FDA did notclear Novavax's NVAX.O traditional protein-based shot and is still reviewing it.
Reporting by Manas Mishra and Mariam Sunny in Bengaluru, Julie Steenhuysen in Chicago; Editing by Pooja Desai
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
